Lexaria Bioscience (NASDAQ:LEXX – Get Free Report) is expected to post its Q4 2026 results on Tuesday, November 24th. Analysts expect Lexaria Bioscience to announce earnings of ($0.90) per share and revenue of $0.05 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 24, 2026 at 12:00 AM ET.
Lexaria Bioscience Stock Performance
Lexaria Bioscience stock opened at $4.41 on Tuesday. Lexaria Bioscience has a 52 week low of $2.43 and a 52 week high of $21.60. The firm has a market capitalization of $9.31 million, a price-to-earnings ratio of -0.87 and a beta of 0.60. The company has a 50 day moving average price of $3.62 and a 200 day moving average price of $8.56.
Analysts Set New Price Targets
Several analysts have issued reports on LEXX shares. Wall Street Zen raised shares of Lexaria Bioscience to a “sell” rating in a research note on Saturday, October 10th. Weiss Ratings cut Lexaria Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Lexaria Bioscience currently has an average rating of “Hold” and an average target price of $22.50.
About Lexaria Bioscience
Lexaria Bioscience is a biotechnology company developing DehydraTECH, a patented technology designed to improve the delivery and absorption of orally administered drugs and other active compounds. The platform incorporates active ingredients into a lipid-based formulation and is being studied for its potential to affect absorption and delivery characteristics. The company’s research has explored applications in areas including hypertension, diabetes and weight management, epilepsy, and antiviral treatments.
See Also
- Five stocks we like better than Lexaria Bioscience
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
